Your browser doesn't support javascript.
loading
Outcomes of prior authorization requests for genetic testing in outpatient pediatric genetics clinics.
Smith, Hadley Stevens; Franciskovich, Rachel; Lewis, Andrea M; Gerard, Amanda; Littlejohn, Rebecca O; Nugent, Kimberly; Rodriguez, Janah; Streff, Haley.
Afiliação
  • Smith HS; Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA.
  • Franciskovich R; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Lewis AM; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Gerard A; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Littlejohn RO; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Nugent K; Department of Pediatrics, Baylor College of Medicine, San Antonio, TX, USA.
  • Rodriguez J; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
  • Streff H; Department of Pediatrics, Baylor College of Medicine, San Antonio, TX, USA.
Genet Med ; 23(5): 950-955, 2021 05.
Article em En | MEDLINE | ID: mdl-33473204
ABSTRACT

PURPOSE:

Genetic testing is an important diagnostic tool in pediatric genetics clinics, yet many patients face barriers to testing. We describe the outcomes of prior authorization requests (PARs) for genetic tests, one indicator of patient access to clinically recommended testing, in pediatric genetics clinics.

METHODS:

We retrospectively reviewed PARs for genetic tests (n = 4,535) recommended for patients <18 years of age (n = 2,798) by pediatric medical geneticists at two children's hospitals in Texas, 2017-2018. We described PAR outcomes, accompanying diagnostic codes, and diagnostic yield.

RESULTS:

The majority (79.9%) of PARs received a favorable outcome. PARs submitted to public payers were more likely to receive a favorable outcome compared with private payers (85.5% vs. 70.3%, respectively; p < 0.001). No diagnostic codes were associated with higher likelihood of PAR approval for exome sequencing. Among the 2,685 tests approved and completed, 522 (19.4%) resulted in a diagnosis.

CONCLUSION:

Though there was a high PAR approval rate, our findings suggest that insurance coverage remains one barrier to genetic testing. When completed, genetic testing had a high yield in our sample. Further evidence of clinical utility and development of clinical practice guidelines may inform payer medical policy development and improve access to testing in the future.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pacientes Ambulatoriais / Autorização Prévia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pacientes Ambulatoriais / Autorização Prévia Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article